

Rula Zain

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1594269/rula-zain-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33
papers

502
citations

12
h-index

21
g-index

39
ext. papers

734
ext. citations

6.7
avg, IF

4.66
L-index

#	Paper	IF	Citations
33	Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukemia?. <i>Scandinavian Journal of Immunology</i> , 2022 , e13153	3.4	1
32	Growth Media Conditions Influence the Secretion Route and Release Levels of Engineered Extracellular Vesicles. <i>Advanced Healthcare Materials</i> , 2021 , e2101658	10.1	2
31	Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 630942	5.7	37
30	Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia. <i>HemaSphere</i> , 2021 , 5, e564	0.3	7
29	Lipophilic Peptide Dendrimers for Delivery of Splice-Switching Oligonucleotides. <i>Pharmaceutics</i> , 2021 , 13,	6.4	3
28	BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. <i>Leukemia</i> , 2021 , 35, 1317-1329	10.7	9
27	Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. <i>Frontiers in Immunology</i> , 2021 , 12, 694853	8.4	9
26	Oligonucleotides Targeting DNA Repeats Downregulate Gene Expression in Huntington's Patient-Derived Neural Model System. <i>Nucleic Acid Therapeutics</i> , 2021 ,	4.8	2
25	Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. <i>Leukemia</i> , 2021 ,	10.7	5
24	Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects. <i>Blood Advances</i> , 2020 , 4, 2439-2450	7.8	9
23	Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases. <i>Neurotherapeutics</i> , 2019 , 16, 248-262	6.4	11
22	Oligonucleotide-Palladacycle Conjugates as Splice-Correcting Agents. <i>Molecules</i> , 2019 , 24,	4.8	8
21	The ability of locked nucleic acid oligonucleotides to pre-structure the double helix: A molecular simulation and binding study. <i>PLoS ONE</i> , 2019 , 14, e0211651	3.7	2
20	Chemical Development of Therapeutic Oligonucleotides. <i>Methods in Molecular Biology</i> , 2019 , 2036, 3-16	1.4	5
19	Combination of Gatekeeper Mutations and Cysteine 481 Replacement Causes Super Resistance to the Irreversible BTK Inhibitors Ibrutinib, Acalabrutinib and Zanubrutinib. <i>Blood</i> , 2019 , 134, 5759-5759	2.2	1
18	Sugar and Polymer Excipients Enhance Uptake and Splice-Switching Activity of Peptide-Dendrimer/Lipid/Oligonucleotide Formulations. <i>Pharmaceutics</i> , 2019 , 11,	6.4	4
17	Therapeutic Oligonucleotides: State of the Art. <i>Annual Review of Pharmacology and Toxicology</i> , 2019 , 59, 605-630	17.9	130

16	Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 504, 749-752	3.4	5
15	Novel peptide-dendrimer/lipid/oligonucleotide ternary complexes for efficient cellular uptake and improved splice-switching activity. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018 , 132, 29-40	5.7	14
14	Role of Pseudoisocytidine Tautomerization in Triplex-Forming Oligonucleotides: In Silico and in Vitro Studies. <i>ACS Omega</i> , 2017 , 2, 2165-2177	3.9	7
13	CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression. <i>Nucleic Acids Research</i> , 2017 , 45, 5153-5169	20.1	15
12	LNA effects on DNA binding and conformation: from single strand to duplex and triplex structures. <i>Scientific Reports</i> , 2017 , 7, 11043	4.9	18
11	Four Novel Splice-Switch Reporter Cell Lines: Distinct Impact of Oligonucleotide Chemistry and Delivery Vector on Biological Activity. <i>Nucleic Acid Therapeutics</i> , 2016 , 26, 381-391	4.8	8
10	Next-generation bis-locked nucleic acids with stacking linker and 2'β-glycylamino-LNA show enhanced DNA invasion into supercoiled duplexes. <i>Nucleic Acids Research</i> , 2016 , 44, 2007-19	20.1	18
9	Delivery, Effect on Cell Viability, and Plasticity of Modified Aptamer Constructs. <i>Nucleic Acid Therapeutics</i> , 2016 , 26, 183-9	4.8	7
8	Disruption of Higher Order DNA Structures in Friedreich's Ataxia (GAA) _n Repeats by PNA or LNA Targeting. <i>PLoS ONE</i> , 2016 , 11, e0165788	3.7	8
7	A distinct triplex DNA unwinding activity of ChlR1 helicase. <i>Journal of Biological Chemistry</i> , 2015 , 290, 5174-5189	5.4	34
6	Development of bis-locked nucleic acid (bisLNA) oligonucleotides for efficient invasion of supercoiled duplex DNA. <i>Nucleic Acids Research</i> , 2013 , 41, 3257-73	20.1	21
5	Structure-specific recognition of Friedreich's ataxia (GAA) _n repeats by benzoquinoxaline derivatives. <i>ChemBioChem</i> , 2009 , 10, 2629-37	3.8	14
4	Benzoquinoxaline derivatives stabilize and cleave H-DNA and repress transcription downstream of a triplex-forming sequence. <i>Journal of Molecular Biology</i> , 2005 , 351, 776-83	6.5	12
3	Triple-helix directed cleavage of double-stranded DNA by benzoquinoxaline-1,10-phenanthroline conjugates. <i>ChemBioChem</i> , 2004 , 5, 1550-7	3.8	26
2	Optimization of triple-helix-directed DNA cleavage by benzoquinoxaline-ethylenediaminetetraacetic acid conjugates. <i>ChemBioChem</i> , 2003 , 4, 856-62	3.8	8
1	Design of a triple-helix-specific cleaving reagent. <i>Chemistry and Biology</i> , 1999 , 6, 771-7		42